Sodium in PDB 7zi2: Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the DCKI2 Inhibitor

All present enzymatic activity of Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the DCKI2 Inhibitor:
2.7.1.113; 2.7.1.74; 2.7.1.76;

The structure of Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the DCKI2 Inhibitor, PDB code: 7zi2 was solved by M.Saez-Ayala, K.Ben-Yaala, S.Betzi, E.Rebuffet, X.Morelli, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	48.72 / 2.18
Space group	P 41 2 2
Cell size a, b, c (Å), α, β, γ (°)	68.836, 68.836, 123.656, 90, 90, 90
R / Rfree (%)	20.1 / 26.2

The binding sites of Sodium atom in the Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the DCKI2 Inhibitor (pdb code 7zi2). This binding sites where shown within 5.0 Angstroms radius around Sodium atom.
In total only one binding site of Sodium was determined in the Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the DCKI2 Inhibitor, PDB code: 7zi2:

Sodium binding site 1 out of 1 in the Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the DCKI2 Inhibitor


Mono view


Stereo pair view

A full contact list of Sodium with other atoms in the Na binding site number 1 of Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the DCKI2 Inhibitor within 5.0Å range: probe atom residue distance (Å) B Occ A:Na303 b:51.6 occ:1.00 O A:LYS42 2.1 45.4 1.0 O A:TRP48 2.3 47.5 1.0 O A:HOH435 2.4 43.2 1.0 O A:SER45 2.6 55.4 1.0 C A:LYS42 3.2 46.7 1.0 C A:TRP48 3.5 47.8 1.0 OE1 A:GLU49 3.5 71.2 1.0 C A:SER45 3.7 53.8 1.0 CA A:LYS42 3.8 51.6 1.0 O A:HOH437 4.1 59.2 1.0 CB A:LYS42 4.2 52.1 1.0 CA A:TRP48 4.2 47.6 1.0 N A:TRP48 4.2 48.9 1.0 CA A:GLU46 4.3 53.5 1.0 CB A:TRP48 4.3 43.7 1.0 N A:GLN43 4.4 49.0 1.0 N A:GLU46 4.4 48.0 1.0 CD A:GLU49 4.5 63.9 1.0 C A:GLU46 4.6 51.2 1.0 N A:GLU49 4.6 54.5 1.0 O A:GLU46 4.8 51.5 1.0 N A:SER45 4.8 45.5 1.0 CA A:GLU49 4.8 55.6 1.0 CA A:GLN43 4.8 55.8 1.0 CA A:SER45 4.9 49.4 1.0 OE2 A:GLU49 5.0 75.0 1.0

M.Saez-Ayala, L.Hoffer, S.Abel, K.Ben Yaala, B.Sicard, G.P.Andrieu, M.Latiri, E.K.Davison, M.A.Ciufolini, P.Bremond, E.Rebuffet, P.Roche, C.Derviaux, E.Voisset, C.Montersino, R.Castellano, Y.Collette, V.Asnafi, S.Betzi, P.Dubreuil, S.Combes, X.Morelli. From A Drug Repositioning to A Structure-Based Drug Design Approach to Tackle Acute Lymphoblastic Leukemia. Nat Commun V. 14 3079 2023.
ISSN: ESSN 2041-1723
PubMed: 37248212
DOI: 10.1038/S41467-023-38668-2